Converge Bio Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.5M

  • Investors
  • 8

Converge Bio General Information

Description

Developer of a generative artificial intelligence platform intended for drug discovery and development purposes. The company's platform provides a library of foundation models trained on biological languages such as DNA, RNA, and protein sequences, offering features for antibody design, target identification, biomarker discovery, and protein manufacturing optimization, enabling biotechnology and pharmaceutical organizations to accelerate research cycles and improve the clinical success rate of novel therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 108 West 13th Street
  • Suite 100
  • Wilmington, DE 19801
  • United States
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • 108 West 13th Street
  • Suite 100
  • Wilmington, DE 19801
  • United States

Converge Bio Timeline

20252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Converge Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 03-Jun-2026 $2.5M Completed Startup
4. Early Stage VC (Series A) 13-Jan-2026 Completed Startup
3. Seed Round 20-Nov-2024 Completed Startup
2. Accelerator/Incubator 12-Sep-2024 Completed Startup
1. Accelerator/Incubator 01-Jan-2024 Completed Startup
To view Converge Bio’s complete valuation and funding history, request access »

Converge Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Converge Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Converge Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a generative artificial intelligence platform intended for drug discovery and development purposes. The com
Discovery Tools (Healthcare)
Wilmington, DE
49 As of 2026

South San Francisco, CA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Converge Bio Competitors (3)

One of Converge Bio’s 3 competitors is Xaira Therapeutics, a Venture Capital-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xaira Therapeutics Venture Capital-Backed South San Francisco, CA
Chai Discovery Venture Capital-Backed San Francisco, CA
Cradle (Healthcare Technology Systems) Venture Capital-Backed Amsterdam, Netherlands
You’re viewing 3 of 3 competitors. Get the full list »

Converge Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Converge Bio Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gates Foundation Not-For-Profit Venture Capital
Bessemer Venture Partners Venture Capital Minority
Saras Capital Hedge Fund Minority
Vintage (Private Equity) Venture Capital Minority
AuroraAxis Capital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Converge Bio FAQs

  • When was Converge Bio founded?

    Converge Bio was founded in 2024.

  • Where is Converge Bio headquartered?

    Converge Bio is headquartered in Wilmington, DE.

  • What is the size of Converge Bio?

    Converge Bio has 49 total employees.

  • What industry is Converge Bio in?

    Converge Bio’s primary industry is Discovery Tools (Healthcare).

  • Is Converge Bio a private or public company?

    Converge Bio is a Private company.

  • What is Converge Bio’s current revenue?

    The current revenue for Converge Bio is .

  • How much funding has Converge Bio raised over time?

    Converge Bio has raised $30.5M.

  • Who are Converge Bio’s investors?

    Gates Foundation, Bessemer Venture Partners, Saras Capital, Vintage (Private Equity), and AuroraAxis Capital are 5 of 8 investors who have invested in Converge Bio.

  • Who are Converge Bio’s competitors?

    Xaira Therapeutics, Chai Discovery, and Cradle (Healthcare Technology Systems) are competitors of Converge Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process